 |
|
|
| |
REAL-WORLD VALUE AND INNOVATION OF DIRECT-ACTING
ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C
AT Kaiser PERMANENTE SOUTHERN CALIFORNIA
|
| |
| |
EASL 2022 June 22-26 London
Lisa M. Nyberg1, Ankita Kaushik2, Nathaniel Smith3, Fadoua El-Moustaid3, Anders H. Nyberg1, Su-Jau Yang4, Kevin M. Chiang5, Alon Yehoshua2
1. Kaiser Permanente, Hepatology Research, San Diego, CA, USA, 2. Gilead Sciences Inc., Foster City, CA, USA , 3. Maple Health Group, LLC, New York, NY, USA 4. Kaiser Permanente, research and evAluation, Pasadena, CA, USA, 5. Kaiser Permanente, National Pharmacy Analytics, Downey, CA, USA
CONCLUSION
Based on this modeling analysis, treating patients with DAAs resulted in a reduction in HCV-related morbidity and mortality and significant improvement in QALYs. Furthermore, use of DAAs was dominant (less costly and more effective) as compared to no treatment offering cost-savings within 3 years post-treatment. These findings highlight the substantial value of DAA treatment offered to HCV patients in the KPSC healthcare delivery system.
|
| |
|
|
|
|
|
